- Home
- ARR vs SRPT Comparison
ARR vs SRPT Comparison
Compare ARR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | SRPT |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2009 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ARR | SRPT |
|---|---|---|
| Price | $15.14 | $20.75 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 29 |
| Target Price | $18.50 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 3.0M | 3.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | ★ 747.06 | N/A |
| EPS | 0.43 | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.72 | ★ $6.84 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $13.98 | $14.68 |
| 52 Week High | $19.31 | $25.32 |
Technical Indicators
Market Signals| Indicator | ARR | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 54.93 |
| Support Level | $15.32 | $20.12 |
| Resistance Level | $17.72 | $23.70 |
| Average True Range (ATR) | 0.24 | 1.55 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 2.84 | 50.28 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.